Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome

Cancer Research

Volumn 60, Issue 24, 2000, Pages 6788-6793

  Sigal, A ^a   Rotter, V ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLINE; DACTINOMYCIN; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GROWTH FACTOR; HEAT SHOCK PROTEIN 70; INTERLEUKIN 6; PROTEIN P53; SOMATOMEDIN C;

ANGIOGENESIS; APOPTOSIS; CARCINOGENICITY; DNA BINDING; GENE MUTATION; GENOME; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; DNA; GENES, P53; HUMANS; MICE; MODELS, BIOLOGICAL; MUTATION; MUTATION, MISSENSE; NEOPLASMS; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034671945     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. p53: Puzzle and paradigm
2. p53, the cellular gatekeeper for growth and division
3. p53 and apoptosis
4. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays
5. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes
6. Analysis of JNK, Mdm2, and p14(ARF) contribution to the regulation of mutant p53 stability
7. Mdm2 promotes the rapid degradation of p53
8. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding
9. Pharmacological rescue of mutant p53 conformation and function [see comments]
10. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells
11. 2-dependent immunoglobulin κ light chain gene expression
12. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage
13. Interference with p53 protein inhibits hematopoietic and muscle differentiation
14. p53 activity is essential for normal development in Xenopus
15. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells
16. Down-regulation of wild type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal
17. Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53
18. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations
19. Inactivation of p53 results in high rates of homologous recombination
20. A model for tumor suppression using H-1 parvovirus
21. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells
22. Identification of minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding
23. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition and transformation suppression
24. In vitro analysis of the dominant negative effect of p53 mutants
25. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation
26. Dominant negative effect of a germ-line mutant p53: A step fostering tumorigenesis
27. Oncogenic forms of p53 inhibit p53-regulated gene expression
28. Meth-A fibrosarcoma cells express two transforming mutant p53 species
29. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation
30. Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization
31. p53 from complexity to simplicity: Mutant p53 stabilization, gain-of- function, and dominant-negative effect
32. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene
33. Gain of function mutations in p53
34. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain
35. Gain-of-function mutations of the p53 gene induce lymphhematopoietic metastatic potential and tissue invasiveness
36. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival
37. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins
38. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens
39. Cooperation between p53-dependent and p53-independent apoptotic pathway of myeloid cells
40. Mutant p53 protein expression interferes with p53-independent apoptotic pathways
41. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
42. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma
43. Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant
44. Anti-apoptotic activity of low levels of wild-type p53
45. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells
46. A common polymorphism acts as an intragenic modifier of mutant p53 behavior
47. Physical and functional interaction between p53 mutants and different isoforms of p73
48. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53
49. Molecular basis for heterogeneity of the human p53 protein
50. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants
51. Activation of C-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain
52. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
53. Modulation of the human interleukin-6 promoter (1L-6) and transcription factor C/EBPβ (NF-IL6) activity by p53 species
54. Response of heat shock element within the human HSP70 promoter to mutated p53 genes
55. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53
56. Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53
57. Identification of genomic DNA sequences bound by mutant p53 protein (Gly245->Ser) in vivo
58. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice
59. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis
60. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome
61. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma
62. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer
63. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
64. Transcriptional regulation of basic fibroblast growth factor gene by 53 in human glioblastoma and hepatocellular carcinoma cells
65. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells
66. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
67. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
68. Comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
69. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
70. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
71. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines
72. Hot-spot mutants of p53 core domain evince characteristic local structural changes
73. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control
74. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines
75. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
76. Structure-based rescue of common tumor-derived p53 mutants
77. Regulation of the specific DNA binding function of p53
78. Allosteric activation of latent p53 tetramers
79. Small peptides activate the latent sequence-specific DNA binding function of p53
80. The DNA binding regulatory domain of p53
81. DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus
82. Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: Implications for regulation
83. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential
84. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
85. Activation of p53 DNA binding activity by point mutation
86. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis
87. IARC p53 mutation database: A relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer
88. Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells
89. Mutagenesis in the p53 gene
90. Activation of the cryptic DNA binding function of mutant forms of p53
91. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53
92. Restoration of the transcription activation function to mutant p53 in human cancer cells
93. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind to its consensus target sequence
94. Reactivation of mutant p53: A new strategy for cancer therapy
95. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations
96. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations
97. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain
98. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
99. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects
100. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
101. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
102. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy